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The European Huntington’s Disease Network (EHDN) commissioned an international task
force to provide global evidence-based recommendations for everyday clinical practice
for treatment of Huntington’s disease (HD). The objectives of such guidelines are to
standardize pharmacological, surgical and non-pharmacological treatment regimen and
improve care and quality of life of patients. A formalized consensus method, adapted
from the French Health Authority recommendations was used. First, national committees
(French and English Experts) reviewed all studies published between 1965 and 2015
included dealing with HD symptoms classified in motor, cognitive, psychiatric, and
somatic categories. Quality grades were attributed to these studies based on levels of
scientific evidence. Provisional recommendations were formulated based on the strength
and the accumulation of scientific evidence available. When evidence was not available,
recommendations were framed based on professional agreement. A European Steering
committee supervised the writing of the final recommendations through a consensus
process involving two rounds of online questionnaire completion with international
multidisciplinary HD health professionals. Patients’ associations were invited to review
the guidelines including the HD symptoms. Two hundred and nineteen statements were
retained in the final guidelines. We suggest to use this adapted method associating
evidence base–medicine and expert consensus to other rare diseases.
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INTRODUCTION
HD is a rare neurodegenerative disorder of the central nervous
system, with a genetic autosomal-dominant inheritance, that
first involves basal ganglia (caudate nucleus and putamen) and
results from expansion of a CAG trinucleotide repeat in the
HTT (huntingtin) gene: alleles with 40 or more repeats are
fully penetrant. The disease is characterized by motor, cognitive
and psychiatric disorders, and a range of somatic symptoms.
Progressive worsening leads to a bedridden state with cognitive
deterioration. Death occurs about 20 years after the onset
of symptoms.
More than a century after the first description of Huntington’s
disease (HD), there is still no curative treatment of the disease;
however, symptomatic treatments are thought to be efficacious in
controlling some of its troublesome symptoms. Yet, symptomatic
management of HD remains inadequately documented (1–4),
which may lead to variations in care mainly based on clinical
experience and not on scientific evidence (5–7).
This document provides scientifically supported and
consensual pharmacological, surgical and non-pharmacological
recommendations for the treatment of HD.
MATERIALS AND METHODS
Methodology
The EHDN guidelines task force developed guidelines
between 2015 and 2018 based on a formalized consensus
method, adapted from the 2015 French Health Authority
recommendations (HAS) (https://www.has-sante.fr/portail/
jcms/c_272505/recommandations-par-consensus-formalize-
rcf). This method combines exhaustive review of the literature,
experts’ proposals, and external scoring of the proposals until
agreement (Figure 1). This is particularly suitable when at
least two of the following conditions are met (1) absence or
insufficiency of high-level evidence specifically addressing the
questions asked; (2) possibility of declining the theme in easily
identifiable clinical situations; (3) controversy, with the need to
identify by an independent group situation in which a practice
is deemed appropriate. Its main advantages are (1) its ability to
identify the degree of agreement or indecision among experts
(2) the strict independence between the steering group, which
formulates the proposals to be put to the vote, and the rating
group which judges the appropriateness.
Search Strategy
First, we conducted a search of scientific evidence published
between 01/01/1965 and 01/08/2015 in the following databases:
Cochrane Library, Embase, MEDLINE, PASCAL, BMJ Clinical
Evidence, Current Contents, Infobanque AMC, National
Guidelines Clearinghouse, PEDro, and BDSP (Public Health
Database) as well as in the following websites: CEBAM, EBM
sources, OMS Réseau de bases factuelles en santé, CBEM
Oxford, Center for Evidence based child health, Center
for health evidence, Center for reviews and Dissemination,
Evidence based neurology, National institute for health and
clinical excellence, Orphanet, ClinicalTrials.gov, OpenSIGLE
(System for Information on Gray Literature in Europe). We
also hand searched abstracts of international congresses of
the Movement Disorders Society. Search terms were chosen
based on a list of symptoms to focus on determined following
discussions within the guidelines committee and working groups
(neuroprotective, rehabilitation, and cognitive) of the European
Huntington’s Disease Network. Search terms were: “Huntington
disease,” “drug therapy,” and symptoms (Huntington chorea,
drug therapy, Chorea, Dystonia, Falls, Chokes, Bradykinesia,
Rigidity, Depression, Apathy, Irritability, aggression, Obsessions,
perseverations, Anxiety, Agitation, Hallucinations, delusions,
paranoia, Impatience, Impulsivity, Suicidal Ideation, Memory,
Loss of fluency, speech, Dysarthria, Attention disorders,
Social cognition impairments, Disorientation, Bradyphrenia,
Indecision, Weight loss, Incontinence, Sleep disorders, Diarrhea,
Sweating, Constipation, Vomiting, Swallowing, Pain, Dental
decay, and Surgery).
Drug manufacturers and authors were also contacted in order
to obtain additional information on unpublished trials. In total
637 publications were collected.
Data Extraction and Analysis
The Task Force committees reviewed the 637 collected
publications with the French and UK committees focusing
on pharmacological/surgical and non-pharmacological
interventions, respectively. First, two members of each
national committee conducted independently a screening
of the collected publications and retained results from clinical
trials, observational studies, meta-analysis, systematic reviews,
case studies, previous recommendations, or conference and
congress summaries. Studies including patients with HD
clinical features and a confirmatory genetic diagnosis or
a compatible family history (mostly for studies published
before gene discovery in 1993) were also included 288 and 88
papers on pharmacological/surgical and non-pharmacological
interventions, respectively, were retained for further analysis.
The remaining members of the Task force validated the list
of excluded publications. Second, a pair of members from
each national committee summarized the key elements of the
retained studies by filling a table with the following columns:
authors, date of publication, type of intervention, daily dose
(both of the active drug and the placebo), genetic characteristics
of the patients (genetically diagnosed), study design, number
of participants, duration of the study, primary and secondary
endpoints, outcome, scales used, conclusion of the reviewers,
and level of proof. Then they analyzed independently each study
by assessing the methods (quality of the study) and results (the
contents of the study) and assigned a level of scientific evidence
according to the HAS classification (see below).
Quality Appraisal and Data Synthesis
Following the HAS recommendations, a quality grade was
attributed to each study according to the level of scientific proof
they provided (Table 1) (Appendix 1).
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FIGURE 1 | Guidelines’ developing stages.
TABLE 1 | Level of scientific evidence and gradation of studies.
Level of scientific proof provided by the
study
Quality grade
Level 1
• Meta-analyses of randomized controlled trials
• Randomized controlled trials of high power
A
Established scientific proof
Level 2
• Randomized controlled trials of low power
• Properly conducted non-randomized
controlled trials
• Cohort studies
B
Scientific presumption
Level 3
Case-control studies
C
Low-level of scientific proof
Level 4
• Comparative studies with major bias
• Case series
Method for Reaching a Consensus
The subsequent steps for developing the guidelines are displayed
in Figure 1. First, the experts of the national committees
formulated provisional recommendations for eachHD symptom,
classified in four categories of disorders (motor, psychiatric,
cognitive, and “others”). Recommendations were based on the
synthesis of information from the studies, i.e., quality grade,
accumulation of scientific evidence, and professional expertise.
Recommendations were rated according to the quality grades
of the studies on which they are based, with the highest
quality grade determining the score. When scientific evidence
was lacking, best clinical practice (professional agreement)
was formulated, based on the experience of the National
committees. The International Steering Committee reviewed the
initial recommendations before initiating process to reach a
consensus with the International Multidisciplinary HD Health
Professionals group (Table 2). This involved two rounds of online
questionnaire completion. After the first round, only appropriate
recommendations with strong consensus were retained (Table 3).
Those without strong consensus were reviewed and modified
by the International Steering Committee prior to the second
round of ranking (Table 3). After the second round, all
recommendations were deemed appropriate, and agreed as such,
except two of the motor chapter and two of the psychiatric
chapter. Two hundred and nineteen statements were retained
in the final guidelines. The steering committee added a rider
considered important by the multidisciplinary group to the four
recommendations that did not reach a consensus. Whereas, the
literature basis scored through survey monkey ends in 2015,
experts’ and knowledge input were provided through the survey
scoring and comments as well as the last face-to-face meeting
until October 2018.
Patients’ Associations Involvement
European, Chinese and French HD associations as well as the
Italian League for Research on Huntington and related diseases
Foundation were invited to review the guidelines.
RESULTS
A condensed version of HD symptoms and recommendations
is provided in the main text. A full version is available
in Appendix 2. Publications justifying the grades of the
recommendations are cited in the text. Recommendations
provided without specific grading are underpinned by
professional agreements.
Given that any HD symptoms may be worsened by stress,
fatigue, and intercurrent disorders (e.g., anxiety, digestive
disorders, infectious or painful conditions, etc.), these aspects
must be assessed and should be treated with appropriate
measures alongside managing the Huntington’s symptoms.
Motor Disorders
The wide spectrum of motor manifestations are the best known
and the most visible symptoms in HD. Among them, involuntary
movements (i.e., chorea) are the most obvious. However, while
the diagnosis of manifest HD is based on the presence of
motor symptoms, these are frequently preceded by cognitive
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TABLE 2 | Composition of the international multidisciplinary HD health professionals.
Motor disorders Cognitive disorders Psychiatric disorders Other disorders
1st survey 2nd survey 1st survey 2nd survey 1st survey 2nd survey 1st survey 2nd survey
Number of participants 67 38 63 36 60 32 56 30
Expertises Dentists 1 1 0 0 0 0 0 0
Geneticists 4 3 3 2 2 0 3 1
Neurologists 39 24 35 20 34 20 33 22
(Neuro)psychologists 8 2 11 6 10 4 7 2
Nurses 3 3 2 2 2 2 3 2
Physiotherapists 5 1 4 2 4 1 3 1
Psychiatrists 7 4 8 4 8 5 7 2
Countries Australia
Belgium
Brazil
Chile
Cyprus
Czech R.
Denmark
Estonia
France
Germany
Hungary
Italy
Netherlands
Peru
Poland
Portugal
Romania
Russia
South Korea
Spain
Sweden
Switzerland
UK
USA
Australia
Brazil
Chile
Cyprus
Czech R.
Denmark
Estonia
France
Germany
Hungary
Italy
Netherlands
Poland
Portugal
Russia
Spain
Switzerland
UK
USA
Australia
Belgium
Brazil
Chile
Cyprus
Czech R.
Denmark
Estonia
France
Germany
Italy
Netherlands
Poland
Portugal
Romania
Russia
Spain
Switzerland
UK
USA
Australia
Belgium
Brazil
Chile
Cyprus
Czech R.
Denmark
Estonia
France
Germany
Italy
Netherlands
Poland
Portugal
Romania
Russia
Spain
Switzerland
UK
USA
Australia
Belgium
Brazil
Chile
Cyprus
Czech R.
Denmark
Estonia
France
Germany
Italy
Netherlands
Peru
Poland
Portugal
Romania
Russia
Spain
Switzerland
UK
USA
Australia
Brazil
Chile
Cyprus
Czech R.
Denmark
Estonia
France
Italy
Netherlands
Peru
Poland
Portugal
Romania
Russia
Spain
Switzerland
UK
USA
Australia
Belgium
Brazil
Chile
Cyprus
Czech R.
Denmark
Estonia
France
Germany
Italy
N. Zealand
Netherlands
Peru
Poland
Portugal
Romania
Russia
Spain
Switzerland
UK
USA
Australia
Brazil
Chile
Czech R.
Denmark
Estonia
France
Italy
Netherlands
Peru
Poland
Portugal
Romania
Russia
Switzerland
UK
USA
and behavioral symptoms (8). While motor symptoms are easily
detected, and might be the source of anxiety and ostracism,
they are often well-tolerated by the patients and their proxies in
contrast to cognitive and behavioral symptoms that often lead to
family and social/professional’s issues.
Chorea
Chorea is characterized by abnormal, involuntary, spontaneous,
uncontrollable, irregular, intermittent, non-rhythmic and aimless
movements affecting the trunk, the face, and the limbs.
Drug treatment should be considered if chorea causes the
patient distress or discomfort.
Tetrabenazine is one of the first-line treatments for this
symptom (Grade A) (9) unless the patient suffers from
not well-managed depression or suicidal thoughts. Second
generation neuroleptics (Grade B) (10, 11) are first-line
treatments for this symptom in particular when the patients
have associated personality and/or behavioral or psychotic
disorders. Monotherapy to treat chorea is preferred because
combination therapy increases the risk of adverse effects and
may complicate themanagement of non-motor symptoms. In the
presence of disturbing chorea, appropriate protective measures
(especially during meal times and during the performance of
instrumental activities of daily living) should be put in place
to avoid traumatic injury or chokes. Rehabilitation specialists
can help identify appropriate assistive technology devices and
positioning techniques.
Dystonia
Dystonia is characterized by abnormal postures that may affect
all body segments and is frequently associated with rigidity (12).
Dystonia intensity varies from a slight intermittent abnormal
posture to severe twitch of muscles with major impact on
movements and functions of daily living.
Both active and passive physiotherapy approaches are
recommended as a preventive measure to maintain the range of
joint motion, limit postural and musculoskeletal deformities and,
prevent the development of contractures. Injection of botulinum
toxin in the case of focal dystonia or to prevent secondary
deformities should be performed by a trained professional.
Customized chairs can provide a comfortable environment in
view of the dystonia-related deformities.
Rigidity
Rigidity is an increase in muscle tone leading to a resistance
to passive movement that can induce joint stiffness and
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TABLE 3 | Rules to determine the strength of the consensus of the multidisciplinary experts.
Recommendations deemed as 1st round 2nd round
Median value Responses’ distribution Submitted to the
2nd round
Median value Responses’ distribution
Appropriate Strong agreement ≥7 All between (7-9) No ≥7 All between (7-9); two
values missing or <7
tolerated
Relative agreement ≥7 All between (5-9) Yes ≥7 All between (5-9); two
values missing and/or <5
tolerated
Inappropriate Strong disagreement ≤3 All between (1-3) No ≤3 All between (1-3); two
values missing or >3
tolerated
Relative disagreement ≤3.5 All between (1-5) Yes ≤3.5 All between (1-5); two
values missing or >5
tolerated
Indeterminate Indecision Between [4–6.5] Whatever the distribution Yes Between [4–6.5] Whatever the distribution
No consensus ≥7 At least one <5 or missing Yes ≥7 At least three <5 or missing
≤3.5 At least one >5 or missing Yes ≤3.5 At least three >5 or missing
limited range of motion, which might be distressing
for patients.
Rigidity may be increased or induced by the use of
neuroleptics or tetrabenazine. If this impacts the functional
capacity of the patient, a reduction in dosage or the withdrawal
of neuroleptics and/or tetrabenazine should be considered
considering overall benefit on chorea and/or behavioral
symptoms vs. severity of rigidity.
Levodopa may provide partial and temporary relief of the
akinetic–rigid symptoms of HD, especially in juvenile forms
(Grade C) (13–18). Treatment with levodopa should be started
gradually and the total daily dose is usually lower than in
Parkinson’s disease.
Physiotherapy is recommended to improve or maintain
mobility and prevent the development of contractures and joint
deformity (Grade C) (19).
Akathisia
Akathisia is a syndrome characterized by unpleasant sensations
of “inner” restlessness that manifests as an inability to sit still.
An iatrogenic cause of akathisia should be investigated as
the priority.
Tetrabenazine (Grade C) (20, 21), neuroleptics and Selective
serotonin reuptake inhibitors (SSRI) may cause akathisia in HD
and reducing the dose or changing the treatment may be helpful.
Swallowing Disorders
Swallowing disorders can occur in patients at the early
stages of the disease and become a major problem in later
stages by inducing repeated choking and leading to secondary
bronchopulmonary infections or even cardiac arrest.
Regular assessment of swallowing disorders should be
provided throughout the progression of the disease (Grade
C) (22) and referral to a Speech and Language Therapist is
recommended as soon as the disorders appear (Grade C) (22–24).
Ancillary assessments that may help in managing swallowing
disorders include: generalized motor skills, respiratory status,
dental health, mood, behavior and emotional status, cognition,
nutrition, and hydration status. Provision of information
and advice on safe swallowing procedures, on posture and
positional changes can help to avoid aspirations and leads to
improvement of swallowing disorders. Oral-facial exercise with
swallow sequence individualization and cough post swallow
may also improve swallowing difficulties. In some cases,
treating chorea might help in improving swallowing problems.
However, side effects of treatments for chorea (e.g., sedation,
attention, and parkinsonism) might also negatively impact
swallowing capacities.
The education of carers is important as they are often
managing the eating, drinking, and swallowing regime.
For severe swallowing disorders impacting nutrition and
quality of life of the patient, the use of a gastrostomy device
Percutanous Endoscopic Gastrostomy (PEG) may be considered
and should be discussed on a case-by-case basis with the patient
and the caregivers. PEG should be anticipated and discussed
with relatives and patients still able to understand the benefits
and burdens of the methods. Before advanced stages of the
disease, patients should be educated to make an informed choice
concerning the PEG methods even if they can change their
decision at any time.
Myoclonus
Myoclonus refers to sudden muscle contractions, brief and
involuntary, axial, in extremities or generalized, similar to spams
and jerks in epileptic seizures but not related epilepsy. In HD,
myoclonus can be observed in a predominant akineto-rigid
phenotype and can be associated with an at rest or action
tremor, especially in the juvenile forms but also in later-onset
forms. In juvenile forms, non-epileptic myoclonus can coexist
with epilepsy.
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In case of myoclonus impacting the functional capacity of
the patients, treatment with sodium valproate or clonazepam,
used alone or in combination, and in escalating doses, is
recommended (Grade C) (25–32). Levetiracetam is a therapeutic
alternative for the same indication. In case of myoclonus of
cortical origin that is not associated with epileptic seizures,
piracetam has a marketing authorization (Grade C) (29).
Benzodiazepines, in particular clonazepam, may be used to
manage myoclonus whilst remaining vigilant with regard to
adverse effects such as somnolence and increasing falls, and the
risk of drug-dependence.
Gait and Balance Disorders
Gait and balance disorders impairments include disruption of
cadence regulation, increased variability of step width and length,
disturbed initiation and increased postural sway (33). These
develop as a result of the progressive complexmovement disorder
seen in HD adding to the overall burden of motor morbidity with
falls and loss of independence in HD (34).
Generally, interventions for gait and balance should start as
early as possible and be continued and adapted throughout the
progression of the disease (Grade C) (33, 35–38). Physiotherapy
interventions (Grade B) (39–42) and the introduction of
falls prevention programs, gait, core stability, and balance
interventions (Grade C) (35, 43–45) as well as attentional training
are recommended.
Pharmaceutical management of chorea may improve walking
and balance as they can be affected by chorea (Grade C)
(46–49). However, they should always be used cautiously and
regularly reassessed as their adverse effects may also aggravate
walking disorders.
Maintaining physical activity and low impact exercises
is recommended.
The use of assistive devices such as four-wheeled walker
(Grade B) (50) as recommended by Physiotherapist or
Occupational Therapist should be considered to improve
stability and reduce fall risk.
Bruxism
Bruxism is an involuntary clenching with excessive contraction
of the jaw muscles. It typically causes lateral movements (or front
to back) responsible for gnashing and can lead to tooth damage.
Injecting botulin toxin A into the masseter muscles is
proposed as the first-line treatment of bruxism (Grade C) (51).
Customized protective mouth guards may be used to reduce the
complications of bruxism on a case-by-case basis, mostly in early
stage patients.
Bruxism may occur as a side effect of neuroleptics (Grade C)
(51, 52) and serotonin reuptake inhibitors, thus reducing their
dose should be considered.
Manual Dexterity
Manual dexterity can be impaired secondary to
chorea/dystonia/akinesia/rigidity but also occur in their
absence—due to abnormal motor planning and sequencing.
Neuroleptics and tetrabenazine may possibly have a beneficial
effect on dexterity as a result of reducing chorea (Grade C)
(46, 47, 53) but may also have a detrimental effect on dexterity
by aggravating other symptoms such as bradykinesia.
Management with physiotherapy and occupational therapy
may be useful to reduce the functional impact of fine motor
skill deterioration (Grade B) (41). Adaptive aids may help to
compensate for the deterioration of manual dexterity.
Global Motor Capacities
Early referral to a physiotherapist is recommended in order
to facilitate the development of a therapeutic relationship,
promote sustainable exercise behaviors and ensure long-term
functional independence.
Physiotherapy and/or personalized exercise programs (Grade
B) (40) are beneficial for the overall functional ability, motor
function, and independence in HD, in combination with
pharmacological treatments (Grade B) (39, 40, 42).
Cognitive Disorders
Cognitive deficits appear frequently before motor symptoms
(8). They are, in addition to behavioral symptoms, the major
cause of family disruption and social withdrawal (54). Cognitive
symptoms cause intense psychological discomfort and a sense of
powerlessness that can lead to behavioral symptoms.
Based on present knowledge, no pharmacological treatment is
recommended for the treatment of cognitive symptoms.
Multiple rehabilitation strategies (speech therapy,
occupational therapy, cognitive and psychomotricity) might
improve or stabilize transitorily cognitive functions at some
point of time in the course of the disease (Grade B) (55).
Executive Functions
Executive functions refer to the functions that allow the
realization of complex task in daily living. They consist in a
set of functions mostly dedicated to cognitive and behavior
control and adaptation, which may be impaired in HD, even
at the premanifest stages and thus impose adaptation from
the environment, organization support including proactivity
in planning appointments, behavior or daily life activities
like cooking.
For the patients to maintain their independence for as long as
possible, it is better to help the patients organize themselves and
initiate activities rather than substitute for them, as long as they
do not endanger themselves.
Treatment for anxiety and depression may help to improve
executive function and cognitive stimulation through
rehabilitation may improve planning and initiation more
specifically (Grade C) (56). Sedative drugs and neuroleptics
should be closely monitored as they impair executive functions
and attention.
Bradyphrenia
Bradyphrenia is defined by slowing of cognitive information
processing and a prolongation of reaction time depending on the
complexity of the cognitive task (57). It becomes more apparent
with HD disease progression.
Management is based on giving the patient enough time
to process information and perform a task and avoiding
time-pressured situations. Cognitive stimulation as part of
rehabilitation may be beneficial.
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Language and Communication Disorders
Language and communication disorders can be divided in speech
and language disorders per se. Speech disorders consist of slurred
and slowed speech causing dysarthria, inappropriate pauses or
bursts of speech, and progressive reduction in verbal fluency
(58). Language (e.g., syntax) impairments appears early in the
disease course, with progressive difficulties in understanding and
producing complex sentences. Reduction of lexical capacities
appears later. This often goes unnoticed and may cause
misunderstanding and impaired communication.
The changing communication needs of the person with
HD should be reassessed throughout the course of the disease
to plan effective management strategies (Grade C) (59). As
communication disorder in HD is variable, its monitoring
requires comprehensive assessment of language and of other
factors such as mood, motivation, and behavior.
Early referral to Speech and Language Therapists is
recommended (Grade C) (59) as they can play a major role
in assessing and managing communication problems in
HD at all stages of the disease. Communication strategies and
techniques may include: management options (e.g., voice therapy
techniques), advice on facilitation of communication (e.g.,
allowing time for communication, reduction of environmental
distractions and noise) and the use of simple technics (e.g.,
gestures and rephrasing) or tools (e.g., pen and phones).
Family members and other communication partners should
be educated to support patients to attempt verbal communication
as long as possible. Augmentative and alternative communication
(talking mats) can compensate for communication difficulties
and increase the individual’s chance of participation in daily
life. These strategies need to be implemented whilst there is still
motivation and a capacity to learn (Grade C) (60).
Social Cognition Impairments
Social cognition impairments refer to a set of symptoms that
affect relationships and social behavior. The most studied are
the inability to recognize emotion others (61) but also to
express emotions, both through facial expression or through the
voice. Executive function impairments can make difficult for the
patients to express their feelings. The capacity to infer other
thoughts or feeling, are also reported to be impaired in patients
(61). Furthermore, motor impairments can create a “facial mask,”
often misunderstood as indifference.
Improvement of behavioral disordersmay help with social and
family integration. However, impact of SSRI or neuroleptics on
social interaction per se has not yet been properly assessed to
allow any recommendation specific to this domain.
Explaining the patients’ disorders to their family, health care
professionals or to their colleagues may facilitate the patient’s
social relationships. Moreover, third party intervention (e.g.,
caregiver, nurse, and social worker) may stimulate patients’
social interaction.
Memory Disorders
Memory disorders are frequently reported in HD and may be
confounded with or exacerbated by attention disorders. They are
mostly characterized by difficulties in learning new information
and retrieving information acquired (62).
Strategies such as establishing and keeping a regular daily
routine may compensate memory loss. Rehabilitative approaches
(speech therapy or neuropsychology) may help memory as part
of an overall intervention plan. Specifically, domain-specific
transcoding (verbal and visual) may help in recalling items.
Sedative drugs, neuroleptics and tetrabenazine may impact
negatively on memory.
Disorientation
Disorientation, both in time and space, appear during
the progression of HD but temporal orientation is altered
earlier (63–66).
Investigations should be carried out to detect any potential
intercurrent cause for a confusional state. Establishing a regular
routine, in tune with the patient’s environment as much as
possible, and milestones enables the patient to manage their
time better.
Visuospatial and Visual Perceptual Disorders
Visuospatial and visual perceptual disorders appear late in the
course of the disease through interference with the integration
and understanding of visual information (66).
It may be useful to make the patient’s environment safe
(padding furniture) to minimize falls and shocks linked to visual
spatial difficulties and aggravated by motor disorders.
Psychiatric Disorders
Behavioral symptoms may appear before the motor diagnosis of
the disease. They are, in addition to and in conjunction with
cognitive symptoms, the major cause of family disruption, social
isolation, and withdrawal.
Their management should be based on the identification of
the underlying triggers causing changes in mood or behavior.
Patients should be given the opportunity to express their worries
and frustrations.
Using methods to calm and reassure patients is a major
component of care of psychiatric disorders. Based on data
from other neurodegenerative conditions, mindfulness-based
cognitive therapy and Acceptance and Commitment Therapy
may be useful in HD.
Depression
Depression is one of the most common psychiatric symptoms
seen in HD (67, 68) with a significant negative impact on quality
of life. It may affect patients at any stage of the disease, even
before motor manifestation (69). Thus, vigilance to detect and
treat depression is required at all stages of the disease.
Psychotherapy and cognitive behavioral therapy may enable
early detection of mood changes. An antidepressant may
be suggested if depression occurs in HD (Grade B) (70).
It is recommended to use a selective SSRI or a serotonin
noradrenaline reuptake inhibitor (SNRI), or alternatively
Mianserin or Mirtazapine, in case of sleep disruption. In case of
recurrent depression, long-term mood-stabilizer treatment may
be introduced in complement to the treatment of the current
episode to prevent relapses. If depression is thought to be an
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adverse effect of other medication, the dosage of the responsible
drug should be reduced gradually. In the case of resistant
depression, or depression associated with psychotic symptoms, a
psychiatrist should be consulted. In case of severe depression and
resistant to oral medications, electroconvulsive therapy (ECT)
may be suggested under the guidance of a psychiatrist (Grade
C) (71–73).
Suicidal Ideation or Attempts
Suicidal ideation or attempts are common in HD (74) and
correlate with family history of suicide, a history of previous
suicide attempts and the presence of depression, especially in
prodromal stages (75).
Suicide risk should be assessed in HD irrespective of the stage,
being particularly vigilant at the time of diagnosis and when the
disease starts to impact on day-to-day life. Prevention of suicide
includes treating risk factors such as underlying depression,
social isolation and impulsivity.
Irritability
Irritability is a very common symptom in HD (67, 68, 76). This
disorder is of fluctuating nature, characterized by impatience and
a tendency to become angry in response to minimal provocation.
Overflow and loss of control are favored by impulsivity, and
can lead to aggressive behavior toward self or others, and rarely,
to criminal behavior. This symptom can be caused by the
frustrations felt by the patient because of the great loss of his
capacities, and by troubles in expressing himself, as well as by
neurological/psychological fatigue brought by the latter.
Before initiating pharmacological treatment, possible
environmental causes for the patient’s frustration and irritability
should be explored. In order to reduce irritability, behavioral
strategies should be considered. A structured plan with a regular
routine in a calming environment is desirable. In addition,
psycho-education for the patient’s family regarding diversion
strategies should be attempted to avoid confrontation as much
as possible.
Whilst SSRIs are first lines for irritability (Grade C) (77, 78),
it may be necessary to use them at or near the maximum
recommended dose in order to be effective. Irritable patients
who do not benefit from an SSRI alone may benefit from
combination therapy with Mianserine or Mirtazapine, especially
when sleep disorders are present. In patients with aggressive
behavior, the recommended first-line treatment is a neuroleptic
(Grade C) (79–81). In case of overt aggression associated with
depression, neuroleptic treatment should be associated with
sedative antidepressants. If irritability does not respond to
antidepressant therapies and/or neuroleptics, a mood stabilizer
(Grade C) (82, 83) can be added.
Apathy
Apathy has been defined by Levy and Czernecki (84) as “a
quantifiable reduction in goal-directed behavior,” manifesting
clinically as a reduction in interest, spontaneity, motivation,
and drive. In patients with HD it is compounded by emotional
blunting, resulting in social withdrawal, and lack of concern
for others. It is the most frequent psychological and behavioral
symptom in HD, especially in the middle and later stages,
causing a severe reduction in the activities of daily living and
often being a source of conflict in the family. With regard to
cognitive and psychological symptoms, apathy and irritability
are the two faces of the same coin (85). A patient can be
apathic the morning and irritable the afternoon, depending
on the situation. As for irritability, apathy can be caused by
environmental and psychological issues. Apathy may also be an
adaptive response when the patient feels overwhelmed by too
much stimulation (HD patients are more sensitive to noise and
environmental interferences), or with the feeling that his/her
disease is progressing.
It is important to explain the various aspects and causes of the
apathy to the family circle.
Personalized cognitive stimulation, establishing routines and
a structured programme of activities is recommended when
possible. A professional intervention at home can improve
compliance and reduce the patient’s opposition and irritability.
Depressionmay increase apathy. If depression is suspected, an
SSRI should be tried.
Sedative medication may increase apathy, thus avoiding
unnecessary prescription or reduce dosage is recommended.
Anxiety
Anxiety as defined by the uncomfortable feeling of nervousness
or worry about something that is happening or might happen
in the future, is common in HD. Anxiety is linked to the
other symptoms (motor and cognitive), as the patient is anxious
because of the loss of essential functions, and correlated to family,
social and economic issues, and to the burden of his pathology
(and the one of his proxies). However, anxiety does not increase
with disease progression. It is associated with depression, suicide,
irritability, quality of life, pain, illness beliefs, and coping.
SSRI or SNRI are first line treatments of anxiety, especially
when associated with depression. On-demand prescription of an
anxiolytic might be beneficial, but caution is required because
of the associated risk of worsening or causing falls. Neuroleptics
(Grade C) (86, 87) are valuable therapeutic alternatives in the
treatment of anxiety when other treatments fail.
Obsessions
Obsessions are defined by recurrent and persistent thoughts,
ideas or images that do not let the mind rest, causing anxiety.
True obsessions, according to this definition, are not very
common in patients with HD, but perseveration is very common,
particularly in the middle and later stages (76). Perseveration
may be defined as the repetition of a thought, behavior or
emotion beyond the psychological context in which it arose, and
in patients with HD these repetitive thoughts and behaviors can
persist for hours, months, or even years after the original trigger.
Patients have little or no insight into the problem (in contrast
to obsessional thoughts, which are distressing and recognized
as abnormal); however, it has been shown that perseveration
is the one behavioral symptom in HD which has a significant
negative impact on the quality of life of family members and
caregivers (88).
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Over the course of HD, symptoms may change and
repetitive thoughts may replace obsessive–compulsive disorder.
The distinction between obsessive–compulsive phenomena and
perseverations is important for the care strategy, both requiring
differential approaches.
If pharmacological treatment is necessary for perseverative
symptoms, an SSRI could be prescribed (Grade C) (89),
in particular when symptoms are associated with anxiety.
Olanzapine and risperidone (Grade C) (81, 86) are two valuable
therapeutics for ideational perseverations, in particular when
they are associated with irritability.
True obsessive–compulsive phenomena are sensitive to
psychological intervention, such as Cognitive Behavioral
Therapy, in non-cognitively impaired patients. If
pharmacological treatment is necessary for obsessive-compulsive
phenomena, a SSRI should be prescribed as first-line treatment
(Grade C) (89).
Impulsivity
Impulsivity consists of acting without prior planning, which can
lead to unpredictable behavior. When impulsivity is associated
with depression or irritability, there is a significant increased
risk of self-harm or suicide or aggressiveness. Impulsivity may
be the result of cognitive impairments, which lead to an intense
frustration toward patience, the patient being in the incapacity to
wait or to deal cognitively with planning. Impulsivity may then
be an adaptive response to language difficulties of patients who
cannot explain what stresses them.
When impulsivity is associated with depression or personality
disorders, there is a risk of auto- or hetero-aggressiveness, which
justifies the prescription of a neuroleptic in combination with a
SSRI. Long-term mood-stabilizer treatment may be introduced
in the case of mood lability and impulsivity.
Sexual Disorders
Sexual disorders are very common in HD. Decreased libido is
the most common symptom while hypersexuality or disinhibited
behavior are rarer, but can cause significant problems in
relationships. Repetitive hypersexual behaviors are often a result
of perseveration.
Identifying the existence of sexual disorders and determining
their triggers and their impact on relationships is important.
Psychological support and/or referral to a specialist in
psychosexual disorders might be useful. In the case of decreased
libido, an iatrogenic cause should be investigated (e.g., the
use of an SSRI) and reducing the dose or substituting the
treatment responsible may be suggested. In the case of erectile
dysfunction, treatment for impotence may be suggested and
seeking the opinion of an endocrinologist and/or a specialist in
psycho-sexual disorders may be useful. In case of impotence,
prescription of phophoesterase 5 inhibitors should be considered
in the clinic when asked for by the patient and his sexual partner.
A behavioral and psychological approach is useful in the case
of hypersexuality, by re-establishing appropriate standards of
behavior in the patient’s social setting. If hypersexuality involves
social discomfort or violence, the proposed first-line treatment is
a neuroleptic (Grade C) (90) and/or a SSRI. If the treatment for
hypersexuality with neuroleptics and/or SSRI is not successful,
the addition of or substitution for an anti-androgen may be
proposed (Grade C) (91–93) under the guidance of a specialist
in sexual disorders or an endocrinologist. Where hypersexuality
poses a risk to others, specific measures should immediately be
put in place (e.g., referral to a psychiatrist).
Hallucinations
Hallucinations are defined as a perception without an object,
at which the subject adheres to and reacts as if the perception
came from outside. Delusions are false beliefs based on incorrect
inferences about external reality, the cultural and social context
to which the patient belongs.
The use by the patient of psychotropic agents should
be searched for and interrupted in case of hallucinations
and delusions. Second generation neuroleptics are the first
line treatment for hallucinations and delusions (Grade C)
(80, 81, 86, 94–106). Clozapine should be proposed as the
first-line treatment in the case of akinetic forms of HD
with debilitating Parkinsonian symptoms. Perseverative ideation
can sometimes mimic psychotic symptoms, and in such
circumstances the patient may benefit from treatment with
serotoninergic antidepressants in combination with an atypical
neuroleptic. Psychiatric intervention and support are particularly
useful in the case of psychotic disorders occurring in HD, for
treatment adjustments. If pharmacological treatments fail, the
option of ECT can be discussed with psychiatrists (Grade C)
(71, 73, 107).
In case of agitation, priority should be given to identifying
environmental or somatic triggers (bladder distension, fecal
impaction, pain, etc.) in order to treat the underlying
cause, especially in the advanced stages of the disease when
communication difficulties exist. When agitation is associated
with an anxiety disorder, a benzodiazepine should be prescribed
as needed to reduce the risk of dependence and falls (Professional
agreement). Some benzodiazepines (e.g., midazolam) may be
useful in emergency situations. Long-term treatment with
benzodiazepines should be avoided as much as possible but
remains necessary in some patients. In the case of extreme
agitation, and if there are associated behavioral and personality
disorders, it is advised to prescribe a neuroleptic (Grade C)
(82, 90, 91, 102, 108, 109).
Other Disorders
Other symptoms than motor, cognitive and psychiatric disorders
are often present. Among those, weight loss, dysphagia, and sleep
disturbance are not unfrequently the most prominent symptoms.
As they may cause discomfort, they should be looked for in order
to limit them when present.
Sleep Disorders
Sleep disorders are common in HD. Around two-thirds of
HD patients suffer from sleep disorders, with diverse causes
such as depression, anxiety, intrinsic alteration in the circadian
sleep-wake rhythm, and involuntary movements during sleep
inducing awakenings (110, 111). They may present as difficulties
in falling asleep and/or early awakenings in the middle of the
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night followed by insomnia. They may be associated with aimless
wandering, and lead to difficulties in coping by the proxies.
However, disturbances of diurnal rhythm (day-night reversal,
etc.) are probably more common than simple insomnia in
HD patients.
Potential underlying cause of sleep-related difficulties
(e.g., depressive syndrome, anxiety, and severe involuntary
movements) should be investigated. Simple lifestyle and dietary
strategies (e.g., avoiding long nap, having no stimulants after
4 pm) are the first-line treatment of insomnia. When lifestyle
strategies are ineffective to treat insomnia, prescribing a hypnotic
may be suggested for a short duration to avoid the risk of
drug dependence. Some agents may be proposed in place of a
hypnotic and for a long duration (e.g., mianserin, mirtazapine,
and antihistaminic drugs) as they have a reduced tendency for
causing dependency. Melatonin may be suggested in case of
sleep phase inversion. A neuroleptic should be prescribed in
the evening when sleep disorders are associated with behavioral
disorders or chorea.
Urinary Incontinence
Urinary incontinence may either be multifunctional or linked
to a deterioration of the frontal lobe control centers, causing an
overactive bladder with urge incontinence and/or unannounced
urination (112).
Where there is urinary incontinence, a precipitating factor
should always be investigated (urinary infection, prostate
disease). It is useful to investigate the presence of diurnal
unexpected complete urination (complete and sudden bladder
emptying, without urge) for which carbamazepine may be of
benefit (Grade C) (112). In the case of an overactive bladder
with leakage and urge incontinence, therapy with selective
antimuscarinic may be tried, whilst watching out for the
appearance of potential side effects, in particular confusional
state. If, after few weeks, the incontinence therapy has not been
effective, it should be stopped. If simple therapeutic measures
have failed, it is advised to undergo urodynamic testing to help
guide the choice of drug therapy and to consult a urologist
if necessary.
In all cases, it is recommended to implement simple lifestyle
strategies: urination before every outing and at regular times.
Pain
Pain assessment is sometimes difficult because of communication
disorders. Moreover, because of communication’s disorders and
a tendency for these patients not to complain, pain is often
related to non-verbal language and behavioral disorders such as
irritability and restfulness.
Behavioral change or worsening of involuntary movements
should trigger the search for an underlying source of discomfort,
and in particular pain.
Dental Pain
Patients suffer from poor oral health for a variety of reasons,
including impaired motor ability (e.g., difficulties brushing teeth)
or reduced motivation to maintain oral health, the use of drugs
affecting salivary secretion and frequent dental trauma due to
falls and injuries, bruxism.
Multidisciplinary teamwork, especially with dietitians to avoid
highly cariogenic foods, is recommended (Grade C) (113, 114).
Verbal and written instructions on how to provide good oral
hygiene at home should be given to patients and carers (Grade C)
(114, 115). Dental care including descaling by a dentist or dental
hygienist should be carried out at least once a year but should be
more frequent in the later stages of the disease.
At later stages of the disease, treatment options should be
discussed carefully and in advance. Treatment intervention,
especially in late stage disease may require conscious sedation
(midazolam, Diazepam) or general anesthesia in a hospital
setting (Grade C) (115–117).
In view of the frequency of digestive disorders in HD (e.g.,
constipation, diarrhea, and vomiting) and their impact on the
quality of life of patients, routine assessment for these symptoms
is recommended in order to ensure their management.
Their diagnostic workup should be conducted by the
relevant specialists (general and digestive examination, biological
and radiological tests, scan, fibroscopy, colonoscopy, etc.).
Fecal impaction should be routinely investigated where there
is constipation/ diarrhea (“false” diarrhea) and/or vomiting.
Vomiting is sometimes intractable. If no specific etiology is
identified, the following should be considered: staggering meals,
reviewing the patients’ posture during and after the meal, and
possibly reducing antichoreic agents, in particular neuroleptics.
Excessive Perspiration
Excessive perspiration can occur at all stages of HD. It can
be associated with other autonomic disorders and reflects
discomfort or emotional burst when sudden.
In the case of excessive perspiration, care must be taken
to ensure patients are well-hydrated, monitored and that their
fluid and electrolyte balance is adjusted. Thyroid function
and the possibility of infection should be assessed in case of
excessive perspiration.
Weight Loss
Weight loss is often present in HD, sometimes prior to the
appearance of other symptoms. It might occur despite normal, or
even high calorie intake, due to a significant energy expenditure
in HD patients. It can also be caused by swallowing disorders,
depressive syndrome with reduced appetite or gastrointestinal
disturbance and gut abnormalities due to enteric neuron
dysfunction (118).
Good nutritional care is a fundamental element of the
management of HD (Grade C) (119, 120). Early assessment
by a dietitian or nutritionist, and regular timely reviews of
nutritional needs are recommended. Factors such as swallowing
ability, cognitive changes, behavior, mood, and general functional
ability should be considered to determine possible other
causes of weight loss (Grade C) (23, 120–123). A multi-
disciplinary approach is recommended andmay include a Speech
Language Therapist and an Occupational Therapist to assist
with swallowing, positioning and feeding aids. Screening tools
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for malnutrition [e.g., malnutrition Universal Screening Tool
(MUST)] are recommended.
A high Body Mass Index (BMI) within normal values should
be maintained if possible and medical and/or social intervention
is recommended when unintended weight loss is higher than
10% within last 3–6 months or when BMI is <20 kg/m2 and
unintentional weight loss of 5% is observed within last 3–6
months. When weight loss is observed, high-calorie and high-
protein food supplements should be prescribed under instruction
and monitored by a dietician/nutritionist (Grade C) (124, 125).
A Mediterranean diet may improve Quality of Life and
nutritional composition (Grade C) (126).
In case of the initiation of antidepressant and/or neuroleptic
treatments, treatments inducing weight gain should be preferred
in patients with significant weight loss, whilst treatments
inducing weight loss should be avoided (these effects can vary
from one patient to another) (Grade C) (127).
Advanced care planning is essential and alternative feeding
methods (PEG, see swallowing disorders) should be anticipated
and discussed with relatives and patients still able to understand
the benefits and risks of the intervention.
Hypersalivation
Hypersalivation can be troublesome in HD patients when
associated with a salivary incontinence (caused by poor oral
occlusion and or fault swallowing).
In the absence of a specific treatment for HD, drugs
used in other chronic diseases may be considered to reduce
salivary secretion: scopolamine given percutaneously, atropine
given orally or other drugs that have an anticholinergic effect
(amitriptyline), whilst watching out for iatrogenic risks, in
particular confusional state, constipation, ocular hypertension
and urinary retention. Injections of botulinum toxin into the
salivary glandsmay be considered in a specialized setting if oral or
oral mucosa treatment options have not induced benefit or were
not well-tolerated.
Reduced Lung Function and Respiratory Muscle
Strength
Reduced lung function and respiratory muscle strength are not
only associated with end stage disease but occur much earlier,
with evidence of some upper airway changes in pre-symptomatic
individuals and reduction of cough effectiveness, reduced lung
volume, and impaired respiratory strength by mid-disease.
Along with changes in posture reduced exercise capacity, these
impairments negatively impact respiratory function, leaving
patients vulnerable to respiratory infections.
Home-based respiratorymuscle training program appeared to
improve pulmonary function in manifest HD patients but had
only a small effect on swallowing function, dyspnea, and exercise
capacity (Grade B) (128).
CONCLUSION
The EHDN guidelines task force provides here scientific and
consensual guidelines from experts from 15 European experts
from the national and steering committees and 73 worldwide
additional experts from 25 countries. Whereas, the literature
extraction and scoring extent from 1965 to 2015, experts’ input
extended until October 2018. To ensure the validity of the
guidelines in the light of the latest scientific results, two authors
reviewed the literature from 2015 to 2019. They extracted 573
abstracts and selected the 17 relevant studies to HDmanagement,
which were then added to the grids. Two authors analyzed
them separately and assigned each of them a level of scientific
evidence. Because these recent relevant studies were not used
to formulate recommendations reviewed by the International
Multidisciplinary HD Health Professionals group, they are
mentioned in the conclusion. Except for deutetrabenazine (Grade
A) (129, 130), none of the studies justified to modify the
recommendations. Deutetrabenazine may indeed be proposed as
an alternative to tetrabenazine for the treatment of chorea in
countries where the marketing authorization is already obtained,
like in the USA. In addition, a number Grade B and C studies
were in agreement with the current recommendations and
reinforce the interest of rehabilitation (131–135). Therefore, as
they stand, with this precision, these guidelines are likely to
serve as international for care in HD. They are likely to support
both general practitioners and specialists’ decisions. Patients
associations and patients themselves may use them and also
disseminate them to inform their doctors.
It becomes increasingly clear that the cost of health is one
of the major issues of public policy. In countries where there
is a medical insurance system, the question of the choice of
therapeutic care or medication and rehabilitation in the insured
basket constitutes a central issue. The difficulty is even greater
in rare diseases such as HD because the number of patients is
too small to carry out double-blind placebo-controlled studies on
large cohorts (Grade A) as required for the selection of health
policies according to evidence-based medicine. In this work,
based on therapeutic trials conducted between 1965 and 2015,
only one grade A study was found among 376 studies analyzed,
which is insufficient to eliminate or recommend enough products
to meet the patients’ needs. In parallel, thanks to specific
international networks dedicated toHD (EHDN,HSG, and ERN)
experts’ know-how has increased with a knowledge-learning
culture over time. In this context, the French Ministry of Health
has labeled Rare Diseases Reference Centers in 2004, imposing
on them various duties, one of which is producing National
Protocols for Diagnostics and Care (NPDC). These protocols are
designed as a combination of comprehensive literature reviews
and expert consensus combining the work of an expert panel,
and then its validation by outside experts to compensate for
the information that is lacking. The recommendations from
these NPDCs made it possible to provide decision-makers with
comprehensive information based on an adapted version of
evidence-based medicine to rare diseases. In addition, they
allowed the health professional to refer to a document to
answer their questions of day-to-day care. EHDN, with more
than 2,000 members in 50 countries, is concerned by the
relevance of prescriptions, medical procedures, hospital stays,
care pathways, and care arrangements. It thus commissioned
an international adaptation of the French NPDC. To give it
an international value, we replaced face-to-face meetings with
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electronic votes and added international committees and patient
associations to national committees. Thus, beyond offering
international guidelines to practitioners for the management of
HD, this document proposes a method that is likely usable in all
rare diseases.
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